Department of Obstetrics & Gynecology, University of Massachusetts Memorial Medical Center, Worcester, MA 01605, USA; University of Massachusetts T.H. Chan Medical School, Worcester, MA 01655, USA.
University of Massachusetts T.H. Chan Medical School, Worcester, MA 01655, USA.
Gynecol Oncol. 2023 Aug;175:128-132. doi: 10.1016/j.ygyno.2023.06.005. Epub 2023 Jun 23.
The prognostic impact of intra-operative tumor spillage (ITS) during minimally invasive surgery (MIS) for endometrial cancer (EC) is not well studied. The objective of this study was to determine if there is an association between ITS and EC recurrence.
We performed a case-control study of patients with a laparoscopic or robot-assisted hysterectomy with EC on final pathology between 2017 and 2022 and compared those with (case) and without (control) a subsequent EC recurrence. Electronic medical records were reviewed for demographic, intra-operative and pathologic details, and recurrence status. ITS was defined as uterine perforation with a manipulator, presence of extra-uterine tumor after colpotomy or specimen delivery, exposure of uncontained specimen into peritoneum, and/or pathology/operative reports noting specimen fragmentation. Conditional logistic regression was used to determine odds ratios for the association of cancer recurrence with ITS. We adjusted for >50% myoinvasion, tumor size, and adjuvant treatment.
1057 patients underwent MIS for EC. Approximately 8% (n = 86) developed recurrent cancer and 172 patients were selected as controls. Twenty percent of recurrent cases (17/86) had ITS compared with 4% of nonrecurrent controls (7/172). When adjusted for tumor size, deep myoinvasion, and adjuvant treatment, patients with ITS had a 5.6 times increased odds (aOR 5.63, 95% CI 1.52-20.86) of recurrence compared to patients without ITS.
In patients with EC, we found an association between ITS and cancer recurrence. These findings warrant further investigation to determine if adjuvant therapy or surgical technique should be altered to improve outcomes.
在子宫内膜癌(EC)的微创外科手术(MIS)中,术中肿瘤溢出(ITS)的预后影响尚未得到充分研究。本研究旨在确定 ITS 是否与 EC 复发有关。
我们对 2017 年至 2022 年期间最终病理诊断为腹腔镜或机器人辅助子宫切除术合并 EC 的患者进行了病例对照研究,并比较了有(病例)和无(对照)随后 EC 复发的患者。回顾电子病历以获取人口统计学、术中及病理细节以及复发情况。ITS 定义为器械引起的子宫穿孔、剖腹术后存在宫外肿瘤或标本输送后、未包裹标本暴露于腹膜内、以及/或病理学/手术报告中提到标本碎裂。采用条件逻辑回归确定癌症复发与 ITS 相关的比值比。我们调整了>50%的肌层浸润、肿瘤大小和辅助治疗。
1057 例患者接受 MIS 治疗 EC。约 8%(n=86)发生复发性癌症,172 例患者被选为对照。20%的复发病例(17/86)发生 ITS,而非复发病例(172/172)为 4%。当调整肿瘤大小、深部肌层浸润和辅助治疗后,发生 ITS 的患者复发的优势比(aOR)为 5.6 倍(aOR 5.63,95%CI 1.52-20.86)。
在 EC 患者中,我们发现 ITS 与癌症复发之间存在关联。这些发现需要进一步研究,以确定是否应改变辅助治疗或手术技术以改善结果。